PRINEVILLE, Ore. — GVB Biopharma, a global producer of cannabinoids, launched its cutting-edge isolation facility, marking a significant leap in production capabilities and efficiency for the company. The new facility, developed over nearly two years of intensive planning and engineering, enables GVB Biopharma to meet the evolving demands of the global hemp and cannabinoid markets by delivering premium-quality isolates at scale.
“Our new isolation facility represents a major milestone for GVB Biopharma,” said CEO Drew Spiegel. “We have designed this operation to ensure ultra-high throughput capacity while maintaining strict nutraceutical cGMP compliance. As a result, we’re positioned to significantly increase production output and meet the rigorous standards required by our ever-expanding, sophisticated customer base.”
“From day one, our focus has been on setting a new industry standard in both scale and precision,” added COO Phil Swindells. “This cutting-edge facility underscores our commitment to delivering top-quality, high-volume cannabinoid isolates. We’re excited to meet the evolving needs of our clients with this unprecedented level of production and consistency.”
Scale and efficiency
The new facility has the capacity to produce more than 300,000 kilograms of isolates per year, representing what the company believes to be the largest cannabis-specific operation of its kind globally. The elevated capacity positions GVB Biopharma to achieve up to $100 million in annual recurring revenue while maintaining the highest level of product integrity and consistency. With significantly larger batch sizes and proprietary separation and refinement processes, the facility delivers higher-efficiency yields than ever before, ensuring GVB Biopharma remains at the forefront of cannabinoid production.
GVB Biopharma’s proprietary methods and unique processes for isolation and refinement are key factors that distinguish it from competitors. These specialized techniques enable the company to achieve high levels of purity and consistency.
Quality and compliance
From the outset, every step of the facility’s development focused on stringent compliance measures. The infrastructure supports nutraceutical cGMP standards to ensure product safety and quality. GVB Biopharma’s commitment to robust quality controls and ongoing efforts toward additional certifications underscore the company’s dedication to best manufacturing practices.
About GVB Biopharma
GVB Biopharma is a global producer of cannabinoids, offering end-to-end solutions for the hemp and cannabis industries. With a commitment to rigorous quality standards, cutting-edge research, and tailored product development, GVB Biopharma continues to drive innovation while meeting the highest benchmarks for safety, potency, and consistency.
